

Name of the Company



KEY IPO Highlights

Subscription Period:

4th Aug., 2021 to 6th Aug., 2021

Issue Size: 13 Mn Shares

(Aggregating up to INR 1213.33 Cr)

(OFS- 813.33 Cr)

Price Band: INR 933 to 954

Lot Size: 15 Shares

Listing Date:

17/08/2021

About the Company:

- One of the fastest-growing diagnostic chains in India.
- Offers a wide range of diagnostic services such as imaging/radiology services (X-rays, MRI, etc.), routine clinical laboratory tests, pathology, and tele-radiology services to private and public hospitals, medical colleges, and community health centres.
- An extensive network of diagnostic centres across India with a key focus on non-metro, and lower tier cities and towns. As of December 31, 2020, it operates 1,801 diagnostic centres that are offering radiology and pathology services across 13 different cities in India. In fiscal 2020, the business has served 5.27 million patients.

Objects of the Issue:

- To finance the cost of establishing diagnostics centres at Punjab, Karnataka, Himachal Pradesh, and Maharashtra.
- Repayment/pre-payment of firm's borrowings fully or partially.
- General corporate purposes.

Financial Overview (INR Million)

Particulars	Mar-21	Mar-20	Mar-19
Total Assets	6,045	6,300	5,290
Total Revenue	6,615*	2,714	2,143
Profit After Tax	1,849	(1,120)	(581)

*INR 2,523 Mn revenue is due to "Gain on fair value movement of Compulsory Convertible Preference Share". Remaining revenue is Operational Revenue and Other Income

P/E MULTIPLE

KRSNAA DIAGNOSTICS	—	78
Metropolis Healthcare	—	81
Dr. Lal Path Labs	—	79
Sector P/E	—	132

Recommendation from major brokerage houses



Kreo Capital Opinion

The company's **strong balance sheet and healthy operating cash flows** should enable to pursue growth opportunities and fund its strategic initiatives. With **promising industry growth prospects** coupled with a **strong execution track record**, we **take positive stand** on this IPO & recommend to invest in this IPO on **long term view**.

Highlights:

- Differentiated diagnostic service provider company in India.
- A comprehensive range of diagnostic services i.e. imaging, pathology, etc.
- Strong brand equity with quality healthcare services at affordable prices.
- Extensive market footprint in 13 states across India.
- Consistent financial performance track record.

Disclaimer: The recommendations stated above are given by individual advisors (including Kreo Capital). Investors are advised to consult their financial advisor and do their own due diligence before subscription.


Key Financial Parameters

Key Financial (FY-21)	Op. Income			OPBDIT		PAT		
	(Rs. Mn)	Y-O-Y Growth (%)	CAGR (FY18-FY21)	(Rs. Mn)	CAGR (FY18-FY21)	(Rs. Mn)	Y-O-Y Growth (%)	CAGR (FY18-FY21)
DLPL	15,818	19%	14%	4366	18%	2,965	30%	20%
SRL	10,321	2%	2%	1711	4%	1,312	53%	20%
Metropolis	9,980	16%	16%	2860	17%	1,832	43%	18%
Thyrocare	4,967	14%	11%	1734	4%	1,132	28%	7%
Krsnaa*	2,883	58%	47%	943	41%	1,849	n.m.	236%
Vijaya	3,766	11%	15%	1660	18%	849	36%	35%
Suburban	1,701	14%	13%	144	n.m.	76	n.m.	n.m.


Source: RHP

*For Krsnaa, Net revenue from operations has been considered which is equal to gross revenue less revenue shared with other hospitals. Gross revenue from operations is INR 3,965 Mn in FY 21.

Operating income CAGR over fiscal 2018 to fiscal 2021 for select diagnostic players compared with the diagnostic industry CAGR over fiscal 2018 to fiscal 2021



CAGR in terms of volume of tests from fiscal 2018 to fiscal 2021



Disclaimer: The recommendations stated above are given by individual advisors (including Kreo Capital). Investors are advised to consult their financial advisor and do their own due diligence before subscription.